Targeted control of pneumolysin production by a mobile genetic

element in *Streptococcus pneumoniae*.

Emily J. Stevens[1]*, Daniel J. Morse[1]*, Dora Bonini[1]*, Seána Duggan[1], Tarcisio Brignoli[1],

Mario Recker[2], John A. Lees[3], Nicholas J. Croucher[3], Stephen Bentley[4], Daniel J. Wilson[5],

Sarah G. Earle[5], Robert Dixon[5], Angela Nobbs[6], Howard Jenkinson[6], Tim van Opijnen[7],

Derek Thibault[7], Oliver J. Wilkinson[8], Mark S. Dillingham[8], Simon Carlile[9], Rachel M.

McLoughlin[9], and Ruth C. Massey[1,10,$].

1: School of Cellular and Molecular Medicine, University of Bristol, Bristol, BS8 1TD, UK.

2: Centre for Ecology and Conservation, University of Exeter, Penryn Campus, TR10 9FE,

UK.

3: MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease

Epidemiology, St. Mary's Campus, Imperial College London, London, W2 1PG, UK.

4: The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton,

Cambridge CB10 1SA, UK.

5: Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford

OX3 7LF, UK.

6: Bristol Dental School, University of Bristol, Bristol, BS1 2LY, UK.

7: Biology Department, Boston College, Chestnut Hill, MA, USA.

8: DNA-Protein Interactions Unit, School of Biochemistry, University of Bristol, Bristol, BS8

1TD, UK.

9: Host Pathogen Interactions Group, School of Biochemistry and Immunology, Trinity

College Dublin, Dublin 2, Ireland.

10: Schools of Microbiology and Medicine, and APC Microbiome Ireland, University College

Cork, Cork, Ireland.

* Contributed equally to this work

$ Corresponding author (email: ruth.massey@bristol.ac.uk or r.massey@ucc.ie)

Keywords: Streptococcus pneumoniae, ICE elements, pneumolysin regulation, ZomB

protein.

Abstract

Streptococcus pneumoniae is a major human pathogen that can cause severe invasive diseases such as pneumonia, septicaemia and meningitis. Young children are at a particularly high risk, with an estimated half a million deaths worldwide in those under five attributable to invasive pneumococcal disease each year. The cytolytic toxin pneumolysin (Ply) is a primary virulence factor for this bacterium, yet despite its key role in pathogenesis, immune evasion, and transmission, the regulation of Ply production is not well defined. Using a genome-wide association approach we identified a large number of potential affectors of Ply activity, including a gene acquired horizontally on the antibiotic resistance conferring Integrative and Conjugative Element (ICE) ICE*Sp*23FST81. This gene encodes a novel modular protein, ZomB, which has an N-terminal UvrD-like helicase domain followed by two Cas4-like domains with potent ATP-dependent nuclease activity. We found the regulatory effect of ZomB to be specific for the *ply* operon, potentially mediated by its high affinity for the BOX repeats encoded therein. Using a murine model of pneumococcal colonisation, we further demonstrate that a ZomB mutant strain colonises both the upper respiratory tract and lungs at higher levels when compared to the wild type strain. While the antibiotic resistance conferring aspects of ICE*Sp*23FST81 is often credited with contributing to the success of the *S. pneumoniae* lineages that acquire it, its ability to control the expression of a major virulence factor implicated in bacterial transmission is also likely to have played an important role.

Introduction

For opportunistic pathogens, such as *Streptococcus pneumoniae*, there is a fine balance to be reached between the ability to colonise the host asymptomatically, to transmit between hosts, and to cause disease symptoms [1-3]. The secretion of cytolytic toxins is often key to this. *S. pneumoniae,* for example, produces pneumolysin (Ply), a cytolytic pore-forming toxin that binds to cholesterol in the membranes of host cells, where it inserts into the lipid bilayer forming a transmembrane pore that lyses the host cell [4-7]. Ply also affects the host immune system in a complex manner, with evidence for both pro- and anti-inflammatory activity [8-11]. The data surrounding the role of Ply in nasal colonisation is complex, with early studies suggesting it contributed positively to the colonisation process [12], but more recent work showing its expression to inversely correlate with colonisation duration and directly correlate with shedding of *S. pneumoniae* from the nose for transmission to new hosts [13-15]. Given the importance of Ply to many aspects of the biology of *S. pneumoniae* it represents an attractive target for the development of therapeutic intervention [16].

Despite its importance, what is perhaps surprising about Ply is that so little is known about its regulation compared to the virulence factors of similar pathogens, such as *Staphylococcus aureus.* To begin to address this, here we sought to define the genetic basis of Ply activity by analysing a collection of 165 isolates belonging to the *S. pneumoniae* PMEN1 lineage [17]. This globally successful clonal group (also known as vaccine serotype 23F, multilocus sequence type 81) is of historical importance having made an important contribution to the emergence of penicillin non-susceptibility amongst the pneumococci [18]. It has acquired further antibiotic resistance through the acquisition of the Integrative and Conjugative Element (ICE) ICE*Sp*23FST81 [8], which confers resistance to tetracycline, macrolides and chloramphenicol, features believed to have contributed to the success of this lineage. As such it represents an important and relevant lineage on which to base this study.

Materials and Methods

Bacterial strains and growth conditions.

Clinical isolates used in this study (listed in supp. table 4) had been previously sequenced

[17] and all belonged to the PMEN1 clone of which *S. pneumoniae* ATCC 700669 is the

reference strain. Strains were grown for 16-24 hours in 5% CO_2 at 37°C, on either brain-

heart infusion (BHI), Todd Hewitt supplemented with 0.5% (w/v) yeast extract (THY), blood

agar plates containing 5% (v/v) defibrinated horse blood, or in BHI/THY broth without blood.

Construction of deletion mutants in *S. pneumoniae*.

Genes were deleted in *S. pneumoniae* using linear PCR products as described previously

[19]. In brief, a stitch PCR approach using the primers listed in Table 1 were used to

generate a single PCR product consisting of 1kb of DNA to either side if the gene to be

deleted, with a gene encoding resistance to erythromycin (*ermAM* - amplified from plasmid

pVA838) in the centre. To transform the bacteria with this PCR product, the wild type

bacteria were grown overnight in 5ml BHI broth, and 2ml of this culture was used to

inoculate a pre-warmed tube of 20ml BHI broth. This was incubated for a further 2 hours,

and 0.5ml was added to 9.5ml pre-warmed BHI broth and incubated for 30 minutes. 1ml of

this sub-culture was transferred to sterile tubes, 10μl of 10μg/ml competence-stimulating

peptide-2 (CSP-2) was added each, and these were incubated for 15 minutes. To 200μl

aliquots of this, either the PCR product or sterile water was added, and the mixture

incubated for a further 2 hours. This was then added to molten BHI agar (10ml) containing

5% (v/v) defibrinated horse blood, allowed to set in a petri dish and incubated for 2 hours.

Plates were then overlaid with a further 10ml molten agar containing 5% (v/v) defibrinated

horse blood with erythromycin (2μg/ml) to selected for successfully transformed cells. Plates

were incubated for up to five days at 37°C, or until colonies appeared within the agar.

Cloning of ZomB for complementation

The *zomB* gene was amplified by PCR from ATCC 700669 using KAPA HiFi HotStart

ReadyMix (Roche) and primers zomBFW: atatgcatgccctcgtaattactaggaaac (SpHI, Tm 67.6

°C) and zomBRV: atatggatccattttcttatcttatagattctaaaatac (BamHI, Tm 63.7) and cloned into

the pVA838 plasmid [20] using MAX Efficiency™ DH5α Competent Cells (Invitrogen) to

make pVA838-zomB. The plasmid was purified and transformed into D39 as described

above, using CSP-1 in place of CSP-2.

Quantification of Ply activity

Strains were grown overnight in BHI broth, then sub-cultured at a 1:1 ratio into fresh broth

and grown for one hour until OD_{600nm} of 0.4-0.7 was reached. These cultures were then

serially diluted 4-fold in a 96 well plate containing BSA assay buffer (0.05g bovine serum

albumin and 77mg dithiothreitol dissolved in 50ml sterile phosphate buffered saline. To each

well, 50µl of triple-washed sheep red blood cells (at a final concentration of 2% diluted in

PBS (v/v)) were added and the plates were incubated for one hour in 5% CO2 at 37°C. The

plates were then centrifuged at 2000rpm for 10 minutes at room temperature to separate the

intact cells from the soluble lysed material. The supernatants from each well were

transferred to a fresh 96-well plate and absorbance values read at 415nm were obtained

using a FLUOstar Omega microplate reader.

GWAS

The initial Genome-wide associations between single nucleotide polymorphisms (SNP) and

bacterial toxicity were determined by means of linear regression. To account for bacterial

population structure, we first performed a singular value decomposition (PCA) of the SNP

data and then used the first four principal components (PC), which together explained

around 45% of the variance, in the regression model

$$toxicity \sim \beta_0 + \beta_1 SNP + \beta_2 PC_1 + \beta_3 PC_2 + \beta_4 PC_3 + \beta_5 PC_4.$$

Statistical significance of the β_1 term was determined at an uncorrected $\alpha = 0.05$ threshold.

Subsequent GWAS analyses of the data by pyseer and BugWas were performed as

previously described [21,22].

Quantification of Ply production

The bacteria were grown overnight in 15ml BHI broth and harvested by centrifugation.

Supernatant proteins were precipitated with 20% trichloroacetic acid, washed 3 times in

acetone and resuspended in 100 µl of 8M urea. The individual proteins were separated on

an SDS-PAGE gels and Western blotting of this conducted using anti-pneumolysin antibody

followed by goat anti-mouse IgG HRP as the secondary antibody. The HRP signal was

detected using the Metal Enhanced DAB Substrate Kit (ThermoScientific).

Quantification of transcription of the *ply* gene

Bacteria were grown overnight in 5-10ml BHI broth and RNA was extracted using a Zymo

Quick-RNA Fungal/Bacterial Miniprep kit following the manufacturer's protocol. Turbo DNase

digest kit was used to remove any contaminating DNA. The quality and quantity of the RNA

was determined using a Nanodrop and the RNA was reverse transcribed to cDNA using a

qScript cDNA synthesis kit (QuantaBio, Beverly, USA), as per the manufacturer's protocol.

RNA samples were standardised such that 100ng was added to each cDNA synthesis

reaction. qPCR was performed using a Mic qPCR cycler (Bio Molecular Systems) and

reactions were set up using a KAPA Sybr Fast universal master mix (no rox). Three

technical repeats were conducted for each cDNA sample and the data analysed using the $2^{-(\Delta Ct\ ply\ -\ \Delta Ct\ recA)}$ method [23]. The cycle parameters included an initial denaturation at 95°C for

3 min, followed by 35 cycles of 95°C for 10 sec, annealing at 60°C for 20 sec, and

elongation at 72°C for 20 sec. A melt curve analysis was performed to check amplified

products. The primer pairs used where *recA* was used as the control housekeeping gene:

ply FW: GAAGACCCCAGCAATTCAAG

ply RV: CCTTGAGTTGTTCCATGCTG

recA FW: ATCGGAGATAGCCATGTTGG

recA RV: ATAGAGGCGCCAAGTTTACG

Expression and purification of ZomB.

The *zomB* gene was cloned into the expression plasmid pET15b, and expressed in *E. coli*

strain BL21(DE3) with a 6x histidine tag at its N-terminus. The *E. coli* cells were grown at

37°C in LB broth containing 100µg/ml ampicillin to an OD_{600nm} of around 0.5, whereupon

cells were temperature acclimatised to 18°C and gene expression was induced for 12 hours

via the addition of 1mM IPTG. Cells were harvested by centrifugation for 20 minutes at

6000rpm and resuspended in buffer containing 50mM Tris pH 7.5,150mM NaCl, 10%

sucrose and 0.1mM PMSF. Cells were lysed by sonication in buffer containing 1mM TCEP,

500mM NaCl, 20mM imidazole and a protease inhibitor cocktail, and cell debris was

removed by centrifugation for 30 minutes at 21,500rpm. Cell lysate was loaded onto a 5ml

HisTrap Nickel binding column which had been equilibrated in HisB buffer (20mM Tris

pH7.5, 500mM NaCl,1mM TCEP, 5% glycerol) plus 20mM imidazole. Proteins possessing

His-tags were eluted with a gradient from 20mM to 500mM imidazole over 32 minutes with a

flow rate of 3ml/min. Protein elution was monitored by measuring absorbance at 280nm.

Fractions containing the most protein were pooled and applied to a HiTrap Heparin affinity

column equilibrated with HepQ/B buffer (20mM TrispH7.5, 1mM TCEP) plus 100mM NaCl.

Heparin-binding proteins were eluted with a gradient from 100mM to 1M NaCl over 30

minutes, monitored by absorbance at 280nm. Two millilitre fractions containing the highest

protein concentrations were pooled and applied to a MonoQ anion exchange

chromatography column equilibrated with HepQ/B buffer plus 100mM NaCl. Proteins were

eluted with a gradient from 100mM to 1M NaCl over 30 minutes, with protein absorbance

monitored at 280nm, and 0.3ml fractions were collected. Fractions containing the highest

concentrations of eluted protein were pooled and stored in HepQ/B buffer plus 330nM NaCl,

corresponding to the salt concentration at which the protein was eluted from the column.

Nanodrop OD$_{280}$ and the ZomB protein's predicted extinction coefficient (118390mol/L/cm)

were used to determine that ZomB had been purified to a concentration of 7.0μM.

Biochemical characterisation of ZomB activity

ATPase activity was measured by coupling the hydrolysis of ATP to the oxidation of NADH

which gives a change in absorbance at 340nm. Reactions were performed in a buffer

containing 20 mM Tris-Cl pH 8.0, 50 mM NaCl, 2 mM DTT, 1 mM MgCl$_2$, 50 U/mL lactate

dehydrogenase, 50 U/mL pyruvate dehydrogenase, 1 mM PEP and 100 μg/mL NADH.

Rates of ATP hydrolysis were measured over 1 min at 25°C and the ssDNA substrate used

was Poly(dT). For calculation of K$_{DNA}$ (defined as the concentration of DNA at which ATP

hydrolysis is half-maximal), the ATP concentration was fixed at 2 mM. The Michaelis-Menten

plot was performed at saturating DNA concentration which is defined as 10x the K$_{DNA}$ value.

The concentration of ZomB was 50 nM in these assays unless indicated otherwise.

Electrophoretic mobility shift assays

The intergenic region between *ply* and the neighbouring gene SPN23F19460, containing

BOX repeat regions was amplified (using the following primers; BoxF:

GAGAGGAGAATGCTTGCGAC and BoxR:

TAGGAATCTCCTTTTTTCACATTTTAATCTTTC). A region of the *ply* gene of equivalent

size was also amplified (using plyF: ATGGCAAATAAAGCAGTAAATGACTTTATAC and

plyR: GCCCCCTAAAATAACCGCCTTC). The purified ZomB protein was added in a range

of concentrations (5μM, 2.5μM, 1.25μM, 0.625μM, 0.3125μM and 0.15625μM) to 10nM

of the PCR products in a buffer containing 20mM Tris (pH 8), 200mM sodium chloride, 1mM

Tris(2-carboxyethyl) phosphine (TCEP) and 10% glycerol. Samples were then run on a 1.5%

agarose gel in 1X TAE buffer for 110 minutes at 90V. Following this, the gel was stained in

TAE containing 1X SYBR Safe DNA gel stain for 30 minutes, and bands were visualised

using a Typhoon FLA 9500.

RNA sequencing

Three independent 20 ml cultures of *S. pneumoniae* ATCC 700669 wild type

and *ΔzomB* mutant were grown overnight in Todd Hewitt broth supplemented with 0.5%

yeast extract, from which total RNA was extracted and DNase treated as described above.

RNA was stored at -70°C until transportation on ice for sequencing at the University of

Bristol Genomics Facility. RNA integrity was determined by electrophoresis using

TapeStation (Agilent) RNA Screentape Assay and samples with scores of > 7 were

considered suitable for library preparation and sequencing.

One hundred nanograms of total RNA was taken into the Illumina TruSeq Stranded Total

RNA with Illumina Ribo-Zero Plus rRNA Depletion kits according to the manufacturer's

instructions. Briefly, the protocol involved enzymatic depletion of ribosomal RNA and clean-

up of the remaining RNA using magnetic beads. The RNA was fragmented and denatured,

and first and second strand cDNA was synthesised, then total cDNA purified using magnetic

beads. The 3' ends were adenylated to prevent blunt end ligation, and indexing adapters

were ligated to the ends of the double stranded cDNA fragments. Magnetic beads

(Agencourt AMPure XP beads, Beckman Coulter) were then used to clean up the cDNA

libraries before amplification of DNA fragments, selecting for adapter molecules. A second

clean up with magnetic beads was performed and the libraries were quantified using the

ThermoFishrer High Sensitivity dsDNA Qubit assay and validated using the TapeStation

(Agilent) with the DNA100 screentape assay. The cDNA libraries were normalised to 4nM

and pooled for sequencing on the Illumina NextSeq500 instrument using a High Output

Version 2.5 sequencing kit. The indices for each sample are detailed in Table 2. The depth

of sequencing covered 2 x 75bp paired end reads, with a minimum of 30 million reads per

sample. Sequence information was output into FastQ file format for subsequent downstream

analysis.
255

Bioinformatic analysis of RNA-sequencing data

FASTQ output files from the Illumina sequencing platform (four files for each forward and

reverse read (one for each lane used in sequencing)) were concatenated into a single file for

each forward and reverse for each sample. The FASTQ files were checked for quality using

FASTQC (version 0.11.9, Brabraham Bioinformatics, UK), ensuring consistency and high-

quality scores, particularly within 'per base sequence quality' and 'per sequence quality

score' tabs. These files were then taken through a bioinformatics pipeline (via terminal on an

Apple MacBook pro running macOS Catalina (version 10.15.7)) detailed below.

An index for the *S. pneumoniae* reference genome (GenBank accession

GCA_000026665.1) was created using Bowtie 2 [24] (version 2.4.1), and FASTQ files were

aligned to this also using Bowtie 2. Overall alignment rate for the samples was between

87.54% to 97.28%. The annotated genome was then used to create a sequence alignment

map (SAM) using SAMtools [25] (version 1.11). Here, a quality control step involved viewing

the header of the files to check for quality scores and correct file format. The SAM files were

sorted and converted to binary alignment map (BAM) files using SAMtools. The annotated

genome was then used as a reference for counting the sorted BAM file reads using Subread

featureCounts [26] (version 2.0.1) including options for paired-end reads.

The featureCounts output file was imported into RStudio (Version 1.2.5033) for differential

expression analysis using DESeq2 [27] (version 1.26.0). The RStudio source code is

available upon request. The aligned BAM files and reference can be obtained at the NCBI

Sequence Read Archive (SRA) under accession PRJNA706751.

Mouse intranasal challenge

8–10-week-old female C57/Black6 mice were inoculated intra-nasally with 1×10^6 CFU of WT,

or an isogenic ZomB deficient strain under isoflurane anaesthetic. Mice were culled at

specific time points post inoculation. The upper respiratory tract was lavaged by the insertion

of a 20-gauge IV catheter into the trachea with 1ml of sterile PBS washed through and

collected at the nose. Lungs were removed and homogenised in 1ml of sterile PBS. Lung

homogenate and nasal lavage, where plated on BHI agar with 5% (v/v) defibrinated horse

blood and 2.5µg/ml tetracycline for enumeration of CFU.

Ethics statement

C57/Bl6 mice were bred in-house in Trinity College Dublin. All mice were housed under

specific pathogen-free conditions at the Trinity College Dublin Comparative Medicines unit.

All mice were used at 8–10 weeks. All animal experiments were conducted in accordance

with the recommendations and guidelines of the health product regulatory authority (HPRA),

the competent authority in Ireland and in accordance with protocols approved by Trinity

College Dublin Animal Research Ethics Committee.

Results

To examine what variability exists in the production of Ply across a collection of closely

related *S. pneumococcal* clinical isolates we first constructed a *ply* mutant in the

pneumococcal PMEN1 isolate ATCC 700669 [8] by replacing the *ply* gene with an

erythromycin resistance cassette. Using this wild type and mutant strain as positive and

negative controls we quantified the Ply activity (lysis of sheep red blood cells (RBCs)) of 165

PMEN1 clinical isolates in triplicate, demonstrating that it varied significantly across this

collection of closely related isolates (Fig. 1a). As the genomes of each of these isolates have

been sequenced [17], we applied three complementary genome-wide association (GWAS)

approaches to identify loci associated with Ply activity. In addition to a linear regression

approach using the SNP (single nucleotide polymorphism) data, we also applied two

methods that make use of kmer (lengths of nucleotide sequences) data: *BugWAS* [21] and

pyseer [22]. The results from each of these methods are presented in supplementary tables

1-3. A Manhattan plot in Fig. 1b shows the significantly associated genetic loci determined

through the SNP-based method, highlighting those loci where two or all three GWAS

methods agreed. (Note, the *P* values are not comparable between the three methods, so this

graph is provided as an illustration of the genomic location of the commonly associated loci).

There were two notable observations from these analyses. The first was that five loci were

associated with Ply activity across all three methods, with the *pbpX* gene, which encodes the

Penicillin Binding Protein 2x, being the most significant. This was followed in order of

significance by the intergenic region between a gene with the locus tag SPN23F05820 and

bgaA, a gene with the locus tag SPN23F00840, the intergenic region between a gene with

the locus tag SPN23F19120 and *msmG,* and the intergenic region between a gene with the

locus tag SPN23F14800 and *greA*. The second notable observation was that 48 individual

genes or intergenic regions on the Integrative and Conjugative Element (ICE)

ICESp23FST81 were associated with Ply activity.

Fitness trade-offs between antibiotic resistance and virulence in bacteria are well established

[28-31], and for both clinical isolates and isogenic mutants the acquisition of penicillin

resistance has been shown to decrease the virulence of *S. pneumoniae* in murine models of

infection [32,33]. Given the association of the *pbpX* gene and Ply activity, we hypothesised

that a similar trade-off may be occurring here, such that the polymorphisms in the *pbpX* gene

may be increasing the levels of resistance to penicillin, which may consequently reduce the

levels of Ply being produced, or vice versa. Although bacterial GWAS results are typically

validated through mutation of the associated locus, the contribution of the protein encoded

by *pbpX* to the biosynthesis of the peptidoglycan layers in the bacterial cell wall is such that

it is essential and cannot be inactivated. Instead, we tested our hypothesis by examining the

levels of resistance to penicillin (minimum inhibitory concentrations, MICs) for the isolates,

but found no significant correlation between the MICs and Ply activity (Pearson product-

moment correlation r^2 = 0.076, P = 0.36). An alternative hypothesis is that the

polymorphisms in the *pbpX* gene affects the stem peptide composition of peptidoglycan, as

this has been shown to inhibit the release of Ply from the bacterial cells [34]. Further work to

test this hypothesis is currently underway.

The high number of associated loci on ICE*Sp*23FST81 is particularly intriguing. This mobile

genetic element (MGE), which can be found both integrated and in plasmid form (illustrated

in Fig. 2a), is believed to be critical to the success of this lineage of *S. pneumoniae* due to

the antibiotic resistance capabilities it brings to the bacteria [8]. Given its ability to move

horizontally as a single contiguous unit between bacteria, it is likely that of the associated

loci only one is an affector of Ply activity, whilst the others are associated through their

physical linkage to this. A survey of the putative activity of all 48 associated loci revealed that

the majority of these are genes typical to such elements, involved in antibiotic resistance and

the mechanics of its movement. An interesting exception is a gene with the locus tag

SPN23F12470. This locus has been annotated as encoding a UvrD-like helicase, a family of

proteins typically associated with core house-keeping activities for bacteria. Further *in silico*

analysis of the encoded protein, that we have named ZomB, suggests that it is a multi-

domain protein with a putative DNA binding helicase domain, followed by two Cas4-like

nuclease domains which are predicted to harbour 4Fe-4S clusters [35] (Fig. 2b). With

several known examples of Cas-like proteins regulating bacterial virulence [36-38], we

hypothesised that it is this gene on ICE*Sp*23FST81 that is the affector of Ply activity.

To establish the role of ZomB in Ply activity we replaced the *zomB* gene with an

erythromycin resistance cassette in *S. pneumoniae* strain ATCC 700669. While no

differences in growth between the wild type and mutant strains was observed, the RBC lytic

activity of the *zomB* mutant was significantly impaired relative to the wild type strain (Fig. 2c).

Using anti-Ply antibodies in a Western blot to understand the mechanism by which ZomB

affects Ply activity, we found that this reduction in lytic activity was due to a decrease in the

amount of Ply protein being released into the bacterial supernatant (Fig. 2d). We also

quantified the relative transcription of the *ply* gene by qRT-PCR and found that the reduced

abundance of Ply was due to a significant decrease (19-fold) in *ply* transcription when the

zomB gene was inactivated (Fig. 2e). Despite numerous attempts to complement this

mutation we were unable re-transform the *zomB* mutant with a plasmid containing the *zomB*

gene, or the empty pVA838 plasmid. So instead, we introduced it into a more genetically

amenable *S. pneumoniae* strain, D39, which does not contain ICE*Sp*23FST81 or the *zomB*

gene. The introduction of the *zomB* expressing plasmid to this strain did not increase the

ability of the strain to lyse RBCs, or increase its production of Ply (Fig. 2c and 2d). However,

the introduction of the *zomB* plasmid significantly increased the transcription of the *ply* gene

in D39, verifying the positive effect ZomB has on *ply* expression (Fig. 2e). It is possible that

the increase in *ply* transcription did not affect the level of Ply production in this strain due to it

being already quite a high Ply producer where it's protein translational machinery or it's

secretory mechanism may already working at a maximal level.

To characterise the biochemical activities of the ZomB protein, we expressed and purified

recombinant ZomB with an N-terminal 6x histidine tag (Fig. 3a). Using a coupled-assay, we

found that ZomB hydrolyses ATP with Michaelis-Menten kinetics and displays a turnover

number of approximately 20 s^{-1} and a K_m value of 90 µM ATP (Fig. 3b). These experiments

were performed in the presence of saturating quantities of ssDNA, which was shown to

strongly stimulate ATP hydrolysis with an apparent dissociation constant of approximately 1

µM (ntds) (Fig. 3c). This behaviour is typical of the UvrD-like DNA helicases of which ZomB

is a member [39]. To examine the putative nuclease activity, ZomB protein (50nM) was

incubated with duplex DNA with and without ATP and Mg^{2+}. Degradation of the DNA by

ZomB was monitored by gel electrophoresis, which showed that the protein possesses a

potent ATP-dependent nuclease activity (Fig. 3d).

Given the *in vitro* DNA binding and nuclease activity of ZomB, and its role in the transcription

of the *ply* gene, we sought to determine the scale of its regulatory activity. To examine this,

we compared the level of transcription of all *S. pneumoniae* strain ATCC 700669 coding

regions between the wild type and *zomB* mutant using RNA-seq. Under the growth

conditions used (i.e. overnight cultures grown in Todd Hewitt broth supplemented with 0.5%

yeast extract), we used a >2-fold difference in expression and a P value of <0.05 following

397 Benjamini-Hochberg adjustment as our significance threshold. We found the transcription of

398 nine genes to be affected by the loss of the *zomB* gene, with those genes encoded within

399 the *ply* locus being the most significantly affected (Table 3, Fig. 4).

401 The *ply* gene is transcribed as part of an operon with four other genes that encode a

402 transcriptional regulator (YebC) and proteins implicated in the movement of Ply from the

403 cytosol to the bacterial cell wall (SPN23F19480-19500) (Fig. 5a) [40, 41]. The operon also

404 contains a BOX repeat region immediately downstream of the *ply* gene. Due to their internal

405 repeating sequences, BOX regions can form stable secondary structures, and their presence

406 has been associated with altered transcription of neighbouring genes [42,43]. The molecular

407 details of how their presence affects gene transcription has not yet been determined but is

408 likely due to these secondary structures where they can either enhance or interfere with

409 transcription processes depending on their relative positioning [43]. As ZomB appears to be

410 a positive effector of *ply* transcription, and given its likely DNA binding capability, we

411 hypothesised that it may directly interact with the *ply* locus, perhaps via its BOX region. To

412 test this we amplified two regions of DNA from within the *ply* locus, one containing the BOX

413 element from within the *ply* operon, as well as an equivalently-sized region of DNA within the

414 *ply* coding region, and performed electrophoretic mobility shift assays (EMSAs) with

415 increasing concentrations of ZomB protein. As visualised in Fig. 5b & 5c, the ZomB protein

416 caused a shift in size of both regions of DNA with a higher level of affinity for the BOX

417 containing DNA evidenced by the shift occurring at lower concentrations of protein and with

418 a clearer (less fuzzy) shift in the DNA. While it is tempting to speculate from this that the

419 effect of ZomB on the transcription of the *ply* locus might be mediated via the BOX region,

420 that the transcription of none of the genes neighbouring the other 136 BOX regions

421 scattered across the *S. pneumoniae* genome were affected by the loss of the *zomB* gene

422 does not support this (Table 1 Fig. 4). But what is clear from this analysis is that the ZomB

423 protein can bind to at least two regions within the *ply* locus with a high affinity, and this is

424 likely to be the means by which it elicits its effect on the transcription of these genes.

The ability of pathogens to alter expression of key virulence factors to counteract host immune responses is a critical strategy of disease tolerance employed by obligate symbionts, such as *S. pneumoniae,* to facilitate persistence within its host [44,45]. In the absence of Ply a reduced local pro-inflammatory response [13,46] coupled with the potential for a more intracellular lifestyle [41,47] has been shown to promote persistence both in the nasopharynx and in the lungs. With Ply expression inversely correlated with colonisation, we sought to determine how ZomB, a regulator of *ply* transcription, would affect *S. pneumoniae* colonisation in a murine model. Mice were inoculated intra-nasally with a sub-lethal dose of either the wild type or ZomB mutant and nasopharyngeal bacterial burden monitored over 7 days (Fig. 6). The ZomB mutant demonstrated increased persistence within the nasopharynx compared to the wild type strain with increased numbers of ZomB mutant bacteria recovered from the upper respiratory tract at days 3 and 7 post inoculation (Fig 6a). Consistent with this, significantly increased levels of pneumococci were also recovered from the lungs of the ZomB mutant challenged animals compared to animals challenged with the wild-type strains on day 7 post colonisation (Fig 6b).

Discussion

Through the application of a functional genomics approach to a large collection of sequenced *S. pneumoniae* isolates, we have identified >100 novel putative affectors of Ply activity (supp. tables 1-3). Of these associated loci we have determined the molecular detail of the interaction between the ZomB protein encoded on ICE*Sp*23FST81 and Ply activity, where ZomB acts as a positive transcriptional regulator of the *ply* operon. We demonstrate that ZomB has ATP dependent nuclease activity and that it can bind with high affinity to multiple regions within the *ply* locus. Further work is required? to understand how the binding of ZomB to this locus affect its transcription, but we hypothesis its role is in the unravelling of secondary structures that would otherwise limit pneumolysin gene transcription.

Amongst the other loci identified by all three GWAS approaches as associated with Ply

production were *bgaA* and *msmG*, two genes involved in carbohydrate utilisation. BgaA is a

surface expressed b-galactosidase known to play a role in pneumococcal growth, resistance

to opsonophagocytic killing, and adherence [48], whereas MsmG is part of the multiple sugar

metabolism system [49]. A close relationship between metabolism and virulence is well

established for other bacterial pathogens [50-52], and this has been recently established for

the pneumococci where a clear link between capsule production and metabolism has been

established. This work suggests that the effect of pneumococcal metabolism on its virulence

may extend beyond capsule production and include an effect of Ply production, which is

currently under investigation.

In this work we have identified and characterised a gene encoded on an MGE with specific

and targeted activity for an operon that is critical to several aspects of the biology of *S.*

pneumoniae. The PMEN1 lineage is believed to have emerged from a relatively

unremarkable background lineage (CC66) to become a globally successful pathogenic

lineage, and this is at least partially attributed to the acquisition of ICESp23FST81 [8,17,18].

This MGE, which is present across the whole PMEN1 lineage, confers resistance to

tetracycline, macrolides and chloramphenicol and thus provides a clear benefit upon

exposure to these antibiotics. However, for many bacterial species antibiotic resistance often

incurs a fitness cost in the absence of the antibiotic, which can be offset, for example, by

reducing the energetically costly production of toxins [28,29]. Here, in stark contrast, we

observe the simultaneous acquisition of increased resistance with increased toxin

production. We believe this work has uncovered an intriguing form of interdependency

between a host bacterium and an MGE, where increased Ply expression due to the

contribution this makes to transmission, has potentially converted a strain from being a

stable coloniser to an efficient transmitter. The long-term benefit the contribution ZomB

makes to this conversion may override the short-term increased energetic costs, potentially

resulting in the evolution of this globally successful pneumococcal lineage.

Authors Statements

Authors contributions: EJS, DJM & DB develop methodology, performed experiment, analysed data and contributed to writing the manuscript. SD & TB provided support and supervision. MR analysed data and contributed to writing the manuscript. JAL, NJC, DJW, SJE & RD analysed data. SB & NJC provided resources. AN, HJ, TvO and DT provided guidance, expertise and resources. OJW and MSD performed experiments and provided advice on helicase proteins. SC and RMM designed performed and analysed the data from the animal experiments, and contributed to writing the manuscript. RCM conceptualised the project, developed the methodology, secured the funding, provided supervisory oversight and wrote the manuscript.

Conflicts of interest: the authors declare that there are no conflicts of interest.

Funding Information: E.J.S. was a BBSRC SWBio DTP funded PhD student. R.C.M. and R.M.M. are Wellcome Trust funded Investigators (Grant reference number: 212258/Z/18/Z). D.J.W. is a Sir Henry Dale Fellow, jointly funded by the Wellcome Trust and the Royal Society (Grant 101237/Z/13/B) and is supported by a Big Data Institute Robertson Fellowship

Acknowledgements: We would also like to thank Prof. Tim Mitchell for helpful discussions during the preparation of this manuscript.

REFERENCES

1. **Deng, X.** *et al.* Whole-genome sequencing reveals the origin and rapid evolution of an emerging outbreak strain of *Streptococcus pneumoniae* 12F. *Clin Infect Dis* 2016;62:1126-1132.
2. **Ioachimescu, O.C., Ioachimescu, A.G. & Iannini, P.B.** Severity scoring in community acquired pneumonia caused by *Streptococcus pneumoniae*: a 5-year experience. *Int J Antimicrob Agents* 2004;24:485-490.
3. **O'Brien, K.L.** *et al.* Burden of disease caused by *Streptococcus pneumoniae* in children younger than 5 years: global estimates. *Lancet* 2009;374**:**893-902.
4. **Canvin, J.R.** *et al.* The role of pneumolysin and autolysin in the pathology of pneumonia and septicaemia in mice infected with a type 2 pneumococcus. *J Infect Dis* 1995;172:119-123.
5. **Hirst, R.A.** *et al.* The role of pneumolysin in pneumococcal pneumonia and meningitis. *Clin Exp Immunol* 2004;138:195-201.

6. **Hirst, R.A.** *et al. Streptococcus pneumoniae* deficient in pneumolysin or autolysin has
reduced virulence in meningitis. *J of Infect Dis* 2008;197;744-751.
7. **Mitchell, A.M. & Mitchell, T.J.** *Streptococcus pneumoniae*: virulence factors and
variation. *Clin Microbiol Infect Dis* 2010;16:411-418.
8. **Croucher, N.J.** *et al.* Role of Conjugative Elements in the Evolution of the Multidrug-
Resistant Pandemic Clone *Streptococcus pneumoniae* Spain23F ST81. *J Bacteriol*
2009;191:1480-9.
9. **Mitchell, T.J.** *et al.* Complement activation and antibody binding by pneumolysin via a
region of the toxin homologous to a human acute-phase protein. *Mol Microbiol* 1991;5:
1883-8.
10. **Paton, J.C., Rowan-Kelly, B. & Ferrante, A**. Activation of human complement by the
pneumococcal toxin pneumolysin. *Infect Immun* 1984;43:1085-7.
11. **Subramanian, K.** *et al.* Pneumolysin binds to the mannose receptor C type 1 (MRC-1)
leading to anti-inflammatory responses and enhanced pneumococcal survival. *Nat*
Microbiol 2019*;*4:62-70.
12. **Kadlioglu, A.,** *et al.* Upper and lower respiratory tract infection by Streptococcus
pneumoniae is affected by pneumolysin deficiency and differences in capsule type.
Infect Immun 2002;70:2886-90.
13. **van Rossum, A.M., Lysenko, E.S. & Weiser. J.N.** Host and bacterial factors
contributing to the clear-ance of colonization by *Streptococcus pneumoniae* in a murine
model. *Infect Immun* 2005;73:7718–26.
14. **Zafar, M.A., Wang, Y., Hamaguchi, S. & Weiser, J.N.** Host-to-Host Transmission of
Streptococcus pneumoniae Is Driven by Its Inflammatory Toxin, Pneumolysin. *Cell Host*
Microbe 2017; 21:73-83.
15. **Riegler, A.N. Brissac, T., Gonzalez-Juarbe, N. & Orihuela C.J**. Necroptotic Cell
Death Promotes Adaptive Immunity Against Colonizing Pneumococci. *Front Immunol*
2019;10:615.
16. **Anderson R, & Feldman C.** Pneumolysin as a potential therapeutic target in severe
pneumococcal disease. *J Infect* 2017;74:527-544.
17. **Croucher, N.J.** *et al.* Rapid pneumococcal evolution in response to clinical
interventions. *Science* 2011;331:430-4.
18. **Wyres, K.L.** *et al.* The multidrug-resistant PMEN1 pneumococcus is a paradigm for
genetic success. *Genome Biology* 2012;13:R103.
19. **Chen, L., Ge, X. & Xu, P.** Identifying essential *Streptococcus sanguinis* genes using
genome-wide deletion mutation. *Methods Mol. Biol* 2015;1279:15-23.
20. **Macrina, F.L., Tobian, J.A., Jones, K.R., Evans, R.P. & Clewell D.B.** A cloning vector
able to replicate in Escherichia coli and Streptococcus sanguis. *Gene* 1982;193:345-53.
21. **Earle, S.G.** *et al.* Identifying lineage effects when controlling for population structure
improves power in bacterial association studies. *Nat. Microbiol* 2016;1:16041.
22. **Lees, J.A.** *et al.* pyseer: a comprehensive tool for microbial pangenome-wide
association studies. *Bioinformatics* 2018;34:4310-2.
23. **Livak, K.J. & Schmittgen, T.D.** Analysis of relative gene expression data using real
time quantitative PCR and the 2(-Delta Delta C(T)). *Methods* 2001;25:402-8.
24. **Langmead, B. & Salzberg, S.L.** Fast gapped-read alignment with Bowtie 2. *Nat.*
Methods 2012;9:357-359.
25. **Heng, L.** *et al.* 1000 Genome Project Data Processing Subgroup, The Sequence
Alignment/Map format and SAMtools. *Bioinformatics* 2009;25:2078-9.
26. **Liao, Y., Smyth, G.K. & Shi W.** FeatureCounts: an efficient general purpose program
for assigning sequence reads to genomic features. *Bioinformatics* 2014;30:923–930.
27. **Love, M.I., Huber, W. & Anders, S.** Moderated estimation of fold change and dispersion
for RNA-seq data with DESeq2. *Genome Biol* 2014;5:550.
28. **Rudkin, J.K.** *et al.* Methicillin resistance reduces the virulence of healthcare-associated
methicillin-resistant *Staphylococcus aureus* by interfering with the *agr* quorum sensing
system. *J Infect Dis* 2012;205:798–806.

29. **Collins, J. *et al.*** Offsetting virulence and antibiotic resistance costs by MRSA. *ISME J*
2010;4:577–84.
30. **Hraiech, S. *et al.*** Impaired virulence and fitness of a colistin-resistant clinical isolate of
Acinetobacter baumannii in a rat model of pneumonia. *Antimicrob. Agents Chemother*
2013;57:5120–1.
31. **Linares, J.F., *et al.*** Overexpression of the multidrug efflux pumps MexCD-OprJ and
MexEF-OprN is associated with a reduction of type III secretion in *Pseudomonas*
aeruginosa. J. Bacteriol 2005;187:1384–91.
32. **Azoulay-Dupuis, E. *et al.*** Relationship between Capsular Type, Penicillin
Susceptibility, and Virulence of Human *Streptococcus pneumoniae* Isolates in Mice.
Antimicrob. Agents Chemother 2000;44:1575–7.
33. **Rieux, V., Carbon, C. & Azoulay-Dupuis, E**. Complex relationship Between Acquisition
of Beta-Lactam Resistance and Loss of Virulence in *Streptococcus Pneumoniae. J*
Infect Dis 2001;184:66-72.
34. **Greene, N.G., Narciso, A.R., Filipe, S.R. & Camilli, A**. Peptidoglycan Branched Stem
Peptides Contribute to Streptococcus pneumoniae Virulence by Inhibiting Pneumolysin
Release. *PLoS Pathog* 2015;11:e1004996.
35. **Zhang, J., Kasciukovic, T. & White, M.G.** The CRISPR Associated Protein Cas4 Is a 5′
to 3′ DNA Exonuclease with an Iron-Sulfur Cluster. *PLoS One* 2012;7:e47232.
36. **Sampson, T.R. *et al.*** A CRISPR/Cas system mediates bacterial innate immune evasion
and virulence. *Nature* 2013;497;254-7.
37. **Heidrich, N. *et al.*** The CRISPR/Cas system in *Neisseria meningitidis* affects bacterial
adhesion to human nasopharyngeal epithelial cells. *RNA Biol* 2019;16:390-396.
38. **Ma, K. *et al.*** cas9 Enhances Bacterial Virulence by Repressing the regR Transcriptional
Regulator in *Streptococcus agalactiae. Infect Immun* 2018;86:e00552-17.
39. **Gilhooly, N.S., Gwynn, E.J. & Dillingham, M.S.** Superfamily 1 Helicases. *Front Biosci*
2013;5:206-16.
40. **Fernebro, J. *et al.*** The influence of in vitro fitness defects on pneumococcal ability to
colonize and to cause invasive disease. *BMC Microbiol* 2008;8:65.
41. **Kimaro Mlacha, S.Z., *et al.*** Phenotypic, genomic, and transcriptional characterization of
Streptococcus pneumoniae interacting with human pharyngeal cells. *BMC Genomics*
2013;14:383.
42. **Croucher, N.J., Vernikos, G.S., Parkhill, J. & Bentley, S.D.** Identification, variation and
transcription of pneumococcal repeat sequences. *BMC Genomics* 2011;12:120.
43. **Knutsen, E. *et al.*** BOX Elements Modulate Gene Expression in *Streptococcus*
Pneumoniae: Impact on the Fine-Tuning of Competence Development. *J Bacteriol*
2006;188:8307-12.
44. **McCarville, J.L. & Ayres, J.S.** Disease tolerance: concept and mechanisms. *Current*
opinion in immunology 2018;50:88–93.
45. **Neill, D.R. *et al.*** Density and duration of pneumococcal carriage is maintained by
transforming growth factor β1 and T regulatory cells. *Am J Respir Crit Care Med*
2014;89:1250-9.
46. **Wolf, A.I. *et al.*** Pneumolysin Expression by Streptococcus pneumoniae Protects
Colonized Mice from Influenza Virus-induced Disease. *Virology* 2014;0:254–265.
47. **Inomataa, M. *et al.*** Macrophage LC3-associated phagocytosis is an immune defense
against Streptococcus pneumoniae that diminishes with host aging. *PNAS*
2020;117:33561–33569 .
48. **Singh AK., et al.** Unravelling the multiple functions of the architecturally intricate
Streptococcus pneumoniae beta-galactosidase, BgaA. *PLoS Pathog* 2014;0:e1004364.
49. **Russell RR., et al.** A binding protein-dependent transport system in Streptococcus
mutans responsible for multiple sugar metabolism. *J Biol Chem* 1992;267:4631-7.
50. **Stevens E., Laabei M, Gardner S, Sommerville GA, Massey RC**. Cytolytic toxin
production by Staphylococcus aureus is dependent upon the activity of the protoheme
IX farnesyltransferase. *Sci Rep* 2017;7:13744.

51. **Bouillaut L, Dubois T, Sonenshein AL, Dupuy B.** Integration of metabolism and
virulence in Clostridium difficile. *Res Microbiol* 2015;166:375-83.
52. **Le Bouguénec C, Schouler C.** Sugar metabolism, an additional virulence factor in
enterobacteria. *Int J Med Microbiol* 2011;301:1-6.

643 **FIGURES**

Fig. 1: Genome wide association study (GWAS) to identify novel effectors of pneumolysin
(Ply) production by *S. pneumoniae*. (**a**) Pneumolysin activity of 165 *S. pneumoniae* of the
PMEN1 lineage, as measured by cell lysis. A wild type (WT) and isogenic pneumolysin
mutant (Δ*ply*) have been included as controls. (**b**) Manhattan plot of the SNP-based GWAS.
The horizontal blue dotted line indicates the threshold for significance (not corrected for
multiple tests). SNPs in loci identified by two or all three GWAS methods are indicated in
blue and orange respectively. The black arrows indicate the regions of interest; 1:
SPN23F00840, 2: *pbpX,* 3: intergenic between SPN23F05820 and *bgaA*, 4: ICESp23FST81,
5: intergenic between SPN23F14800 and *greA,* and 6: intergenic between SPN23F19120
and *msmG.*

2a

2b

ZomB protein (approx. 150kDa)

2c
RBC lysis (A₄₁₅)

2d
Ply

2e
ply transcript level (relative to recA)

Fig. 2: Inactivation of the *zomB* gene on the ICESp23FST81 affects pneumolysin production. **(a)** Cartoon illustration of ICESp23FST81 in both its linear chromosomally integrated form and circularised plasmid form. Some genes of interest have been included: SPN23F12410, SPN23F13170 and *rplL* because these flank the element in its linear form and come into close association when in the plasmid form. Genes encoding the antibiotic resistance genes for chloramphenicol and tetracycline are also indicated. **(b)** Schematic of the ZomB protein with its helicase and two Cas4-like nuclease domains indicated. (**c**) The lytic activity of the *zomB* mutant is comparable to that of the *ply* mutant as determined by a sheep RBC lysis assay in the ATCC 700669 strain. In the D39 strain the introduction of the

zomB gene on the pVA838 plasmid did not affect the RBC lytic activity of the bacteria. (**d**)
The presence of Ply in the extracellular medium is reduced in the *zomB* mutant in the ATCC
700669 strain, determined using anti-Ply antibodies in a Western blot on concentrated
bacterial supernatant. In the D39 strain the introduction of the *zomB* gene on the pVA838
plasmid did not affect the level of Ply production. (**e**) The inactivation of *zomB* in the ATCC
700669 strain reduces the transcription of the ply gene, and the introduction of the *zomB*
gene into the D39 strain increase *ply* transcription. The transcription of *ply* was determined
by qRT-PCR, where the data was made relative to the expression of the housekeeping gene
recA in each sample and normalised to the level of expression on the *ply* gene in the wild
type strain. The box plots represent the median and interquartile ranges; individual data
points are indicated by open circles.

Fig. 3: The ZomB protein has ATP dependent nuclease activity. (**a**) An SDS-PAGE gel
showing the purified his tagged ZomB protein. (**b**) Steady-state ATPase activity of ZomB (50
nM) was measured at saturating ssDNA concentration to determine the Michaelis-Menten
parameters. (**c**) Steady-state ATPase activity of ZomB is strongly stimulated by ssDNA with
an apparent dissociation constant of approximately 1 µM ntds. (**d**) Nuclease assays were
performed with linear DNA demonstrating that it was degraded by the ZomB protein in the
presence of both ATP and divalent cations.

729 **Fig. 4:** ZomB is a positive regulator of the *ply* operon. The transcription of coding regions
730 across the wild type *S. pneumoniae* and ZomB mutant were compared by RNAseq. Only
731 nine genes were significantly affected, and of those the most affected were *zomB* and the
732 five genes encoded on the *ply* operon.

741
742

Fig. 5: The ZomB protein specifically binds to the BOX region within the Ply encoding operon. (**a**) cartoon of the *ply* encoding operon with the *yebC* and *ply* genes, the SPN23F-locus tags of the neighbouring genes, and promoter and transcript length (black arrow) indicated. (**b**) EMSAs demonstrating the specificity of binding of the ZomB protein for two regions within the *ply* locus. The concentrations of ZomB used were 2.5, 5, 10, 20, 40 and 80nM.

Fig. 6: ZomB has a negative effect on the nasal colonisation of mice by *S. pneumoniae*. (**a**)
Groups of C57Blk mice were inoculated intranasally with wild type *S. pneumoniae* or an
isogenic ZomB mutant. At specific time points post colonisation the upper respiratory tract
was lavaged with sterile PBS and the bacterial burdens in the lavage fluid quantified (**a**) and
the lungs removed, homogenised and the bacterial burdens quantified to determine lower
respiratory tract colonisation levels (**b**). The data from each mouse and sample are provided
with the mean CFU +/- the standard error of the mean indicated. Statistical analysis was
performed using a Kruskal-Wallis test with Dunn's Multiple Comparisons. *$P < 0.05$.

 TABLES

802 **Table 1:** Primers used to construct mutants.

Amplification site	Primer Sequence
ply (LHS) forward	5' CCCTTGCTCTGGTTAAAAAAAGAAGC 3'
ply (LHS) reverse	5' ATATTTTTGTTCATATTTGCCATCTTCTACC 3'
ery-ply forward	5' GGTAGAAGATGGCAAATATGAACAAAAATATAAAA 3'
ery-ply reverse	5' CTACCTGAGGTTATTTCCTCCCGTT 3'
ply (RHS) forward	5' GAGGAAATAACCTCAGGTAGAAGATAAG 3'
ply (RHS) reverse	5' GATCACCTTTTTTAGCTGCTACATAG 3'
zomB (LHS) forward	5' TGCCCACTATTTTTATCTAGTTGCTTACC 3'
zomB (LHS) reverse	5' ATTTTTGTTCATTGTTGTCATCGTTTTACCTC 3'
ery-zomB forward	5' CGATGACAACAATGAACAAAAATATAA 3'
ery-zomB reverse	5' CTTTTCCGGATTCTTATTTCCTCCC 3'
zomB (RHS) forward	5' GGAGGAAATAAGAATCCGGAAAAG 3'
zomB (RHS) reverse	5' AATTAATTCCTGAATACAAGTTAACAAAATAG 3'

805 **Table 2:** Sample indices for sequencing.

Sample	Index 1 (i7)	Index 2 (i5)
WT1	CCGCGGTT	CTAGCGCT
WT2	TTATAACC	TCGATATC
WT3	GGACTTGG	CGTCTGCG
zomB1	AAGTCCAA	TACTCATA
zomB2	ATCCACTG	ACGCACCT
zomB3	GCTTGTCA	GTATGTTC

806
807
808
809

810 **Table 3:** Transcriptional differences between the *zomB* mutant relative to the wild type
811 strain. The locus tags in bold indicate those encoded within the *ply* operon.

Locus Tag	Fold Change (Log2)	P values (adjusted)	Gene Product
SPN23F11770	1.8	2.3×10^{-5}	ABC-F family ATP-binding cassette domain-containing protein
SPN23F12440	1.1	9.3×10^{-3}	Plasmid mobilization relaxosome protein MobC
SPN23F12470	-7.1	7.8×10^{-113}	ZomB protein
SPN23F19450	-2.5	3.1×10^{-3}	MarR family transcriptional regulator
SPN23F19460	-2.7	1.3×10^{-30}	YebC DNA-binding transcriptional regulator
SPN23F19470	-4.8	4.4×10^{-49}	Pneumolysin
SPN23F19480	-4.9	4.1×10^{-38}	Hypothetical protein
SPN23F19490	-5.2	5.5×10^{-30}	Hypothetical protein
SPN23F19500	-5.0	6.4×10^{-24}	DUF4231 domain-containing protein